key: cord-0694141-qd03otwu
authors: Connolly, Caoilfhionn M.; Boyarsky, Brian J.; Ruddy, Jake A.; Werbel, William A.; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline M.; Segev, Dorry L.; Paik, Julie J.
title: Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series
date: 2021-05-25
journal: Ann Intern Med
DOI: 10.7326/m21-1451
sha: 67d63184d68c9389e100c93b38f542cba526e4cf
doc_id: 694141
cord_uid: qd03otwu

nan

have been shown to reduce humoral response to both influenza and pneumococcal vaccines (4) , impairment of vaccine response by other conventional disease-modifying antirheumatic drugs has not been shown. However, mycophenolate has recently been associated with a diminished humoral response to the first dose of SARS-CoV-2 mRNA vaccination in transplant recipients and patients with RMDs (1, 2) .

A unifying factor among patients in this case series was the use of either a B-lymphocyte-depleting agent or medication that affects lymphocytes. This supports the critical role of B-cell immunocompetence in generating appropriate response to vaccine antigen and contrasts with the robust anti-RBD responses seen in other patients with RMDs (2) . Of note, participants reported rituximab infusion at a median of 14 weeks before the first vaccine dose. Rituximab has been associated with worse outcomes in patients with RMDs and SARS-CoV-2 infection (5), and thus it is of further concern that these patients may not derive protection from vaccination.

Limitations of this study include its lack of external validity given homogeneity in age and sex of the case series as well as its nonrandomized design.

Additional research is required to further characterize the humoral and cellular responses to SARS-CoV-2 vaccination in patients with RMDs. Optimization of vaccine response in patients receiving B-cell-modulating agents may require perivaccination adjustment in dosing and timing of these agents. Patients receiving these medications should be aware of the potential for suboptimal vaccine response and the need for ongoing vigilance in observing nonpharmacologic preventive measures. 

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases

Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation

COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry